News headlines about Imperva (NASDAQ:IMPV) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Imperva earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news articles about the software maker an impact score of 44.8319642035873 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern’s analysis:
- Imperva Inc (IMPV) Receives Consensus Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- New Research Coverage Highlights Orbital ATK, Imperva, Dave & Buster’s Entertainment, Flagstar, W.R. Grace, and ChromaDex — Consolidated Revenues, Company Growth, and Expectations for 2018 (markets.financialcontent.com)
- Carillon Tower Advisers Inc. Invests $36.80 Million in Imperva Inc (IMPV) (americanbankingnews.com)
- Brokerages Expect Imperva Inc (IMPV) Will Post Quarterly Sales of $84.18 Million (americanbankingnews.com)
- Imperva Inc (IMPV) CRO Sells $1,153,739.72 in Stock (americanbankingnews.com)
Imperva (NASDAQ:IMPV) opened at $46.65 on Thursday. The stock has a market capitalization of $1,590.00, a P/E ratio of 69.63 and a beta of 1.79. Imperva has a fifty-two week low of $37.17 and a fifty-two week high of $52.40.
Several equities research analysts recently commented on the company. ValuEngine upgraded Imperva from a “sell” rating to a “hold” rating in a research report on Thursday, February 15th. Piper Jaffray Companies upgraded Imperva from a “neutral” rating to an “overweight” rating and set a $52.00 target price on the stock in a research report on Friday, February 9th. Oppenheimer restated a “buy” rating and set a $55.00 target price on shares of Imperva in a research report on Thursday, November 9th. Evercore ISI restated a “buy” rating and set a $56.00 target price on shares of Imperva in a research report on Wednesday, November 8th. Finally, JPMorgan Chase & Co. lowered Imperva from a “neutral” rating to an “underweight” rating and set a $45.00 target price on the stock. in a research report on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $53.14.
In other Imperva news, CRO Michael D. Mooney sold 24,454 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $47.18, for a total value of $1,153,739.72. Following the transaction, the executive now owns 24,454 shares in the company, valued at $1,153,739.72. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Anthony J. Bettencourt sold 66,037 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $46.98, for a total value of $3,102,418.26. Following the completion of the transaction, the director now owns 66,037 shares in the company, valued at approximately $3,102,418.26. The disclosure for this sale can be found here. 1.90% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3229874/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-imperva-impv-share-price.html.
Imperva Company Profile
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.